Faruqi & Faruqi Urges Regeneron Investors to Seek Counsel
Law firm Faruqi & Faruqi has urged investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who have suffered losses to contact them before the September 14, 2026 deadline.
The law firm Faruqi & Faruqi, LLP has alerted investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who experienced losses to consider their legal options ahead of the September 14, 2026, lead plaintiff deadline.
This action targets individuals who incurred financial losses through trading Regeneron's securities. Faruqi & Faruqi, LLP, a firm specializing in securities litigation, is offering consultations to those affected.
James (Josh) Wilson, a partner at Faruqi & Faruqi, LLP focusing on securities litigation, encourages investors to reach out directly to discuss their specific situations and potential courses of action. The firm aims to advise investors on their rights and available remedies.
The litigation concerns alleged violations of securities laws. Investors who believe they have been impacted are advised to contact the firm. The September 14, 2026 deadline is significant for the appointment of a lead plaintiff in the securities class action.